Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of Manchester Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of St Andrews Featured PhD Programmes
University of Glasgow Featured PhD Programmes
University of Reading Featured PhD Programmes
"glioblastoma"×
10 miles

glioblastoma PhD Projects, Programs & Scholarships

We have 12 glioblastoma PhD Projects, Programs & Scholarships

  • "glioblastoma" ×
  • clear all
Order by 
Showing 1 to 10 of 12
  Non-canonical G protein signalling of US28 as a new target for glioblastoma
  Research Group: Centre for Experimental Medicine
  Dr B Plouffe, Dr E Evergren, Prof C Taggart
Application Deadline: 20 January 2019
Glioblastoma (GBM) is a very aggressive type of brain cancer with an extremely poor prognosis. For most of GBM cases, infection by the human cytomegalovirus (HCMV) expressing the chemokine receptor US28 is responsible of this disease.
  Role of hypoxia in promotion of higher grade glioblastoma
  Research Group: Institute of Cancer Therapeutics
  Dr V Vinader, Dr K Afarinkia
Applications accepted all year round
Glioblastomas are categorized into four grades. Grade I is essentially benign and slow growing, and most amenable to treatment. Grade II tumors are larger and invade surrounding tissue.
  MRC Precision Medicine DTP: Mapping the transcriptomic, genomic and breakomic landscape of radiation resistance in pancreatic carcinoma and glioblastoma
  Research Group: Institute of Cancer Sciences
  Dr D Chang, Dr R Carruthers
Application Deadline: 7 January 2019
Supervisors. Dr David Chang. Dr Ross Carruthers. PhD project summary. The determinants of response to radiotherapy in common tumour sites remain largely enigmatic, with no clinically useful biomarkers of radiation sensitivity being available.
  MRC DiMeN Doctoral Training Partnership: Gene expression network analysis to identify candidate drivers of treatment resistance in glioblastoma multiforme
  Dr A Droop, Dr L Stead, Prof D R Westhead
Application Deadline: 21 January 2019
Glioblastoma (GBM) is an incurable brain cancer. Patients survive an average 14 months post-diagnosis, despite receiving surgery and intensive chemoradiation because 100% of tumours grow back.
  The IGF axis as a mediator of treatment resistance in glioblastoma multiforme
  Prof V Macaulay, Prof N Sibson
Application Deadline: 11 January 2019
Despite multimodality treatment with surgery, ionising radiation (IR) and chemotherapy, the outlook for patients with glioblastoma multiforme (GBM) is extremely poor.
  Development of novel inhibitors for the treatment of Glioblastomas
  Dr S Ahmed, Dr S Darby
Applications accepted all year round
Glioblastoma (GBM) is the most common form of brain tumour in adults and is incurable. Despite optimal treatment consisting of surgery, chemotherapy and radiotherapy, median survival is 15 month.
  MRC Precision Medicine DTP: Quantitative proteomic analysis of dysregulated adhesion protein localisation in patient-derived cancer cells
  Research Group: Edinburgh Cancer Research Centre
  Dr A Byron, Prof M Frame, Prof R Zubarev, Dr A Sims
Application Deadline: 7 January 2019
Summary. This project seeks to use proteomic data and computational approaches to identify signatures of cell adhesion proteins that are mislocalised in cells from brain cancer patients.
  MRC DiMeN Doctoral Training Partnership: Development and application of fast Magnetic Resonance Spectroscopic Imaging methods for neuro-chemical profiling
  Prof J Schneider, Dr S Short
Application Deadline: 21 January 2019
While Magnetic Resonance Imaging is well established to assess anatomy, structure and function in patients and in animal models of human disease alike, (routine) MR Spectroscopy tools to investigate metabolic alterations are far less common.
  How does amino acid metabolism affect tumour growth?
  Dr L. Cheng
Applications accepted all year round
The effect of diet on tumour growth is hotly debated but poorly characterized. Due to the heterogeneous nature of the tumours, dietary studies in patients with varied genetic background often led to inconclusive outcome.
  Understanding the molecular mechanisms which drive brain cancer recurrence and defining novel therapies to target these aggressive tumour cell populations
  Dr B Day
Application Deadline: 30 April 2019
Glioblastoma (GBM) is the most common and aggressive adult primary brain cancer. Median survival is. As part of the QIMR-Berghofer Brain Cancer Tissue Bank, we have collected a series of patient specimens which include primary tumours that have not undergone treatment and matching post-treatment recurrent tumours.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.